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Abstract 
This study aimed to determine whether brain-derived neurotrophic factor 
(BDNF) variants are related to premorbid educational attainment, progression of 
cognitive and functional decline, and associated neuropsychiatric symptoms in patients 
with Alzheimer’s disease (AD). A sample of n = 341 AD subjects was genotyped for the 
BDNF polymorphisms val66met, C270T, and G-712A. Subjects received tests of 
cognition and daily function at baseline and at multiple subsequent time points during 
their participation in a variety of research protocols. Cognition was measured by the 
Mini-Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale 
(ADAS-Cog). Functional performance was assessed using the Instrumental Activities of 
Daily Living questionnaire (IADL) as well as the Alzheimer’s Disease Cooperative 
Study-Activities of Daily Living inventory (ADCS-ADL).  Subjects were also 
characterized for the frequency and severity of neuropsychiatric symptoms using the 
Neuropsychiatric Inventory (NPI). There was a significant effect of val66met genotype 
on educational attainment (F = 7.42, df = 2, 329, P = .00070), with met homozygotes 
having significantly fewer years of education than both the val/met and val/val groups. 
No association was observed between any BDNF polymorphism and measures of 
cognitive or functional decline. The C270T-T allele was associated with a higher 
prevalence of neuropsychiatric symptoms (Z = -2.11, N = 241, p = .035) and specifically 
with the presence of hallucinations (OR = 3.25, 95% CI = [1.22-8.62], p = .018). In 
summary, the val66met polymorphism appears to be associated with lower premorbid 
educational attainment in AD patients. The C270T-T allele demonstrated association with 
total neuropsychiatric symptoms and specifically hallucinations.  BDNF genotypes in this 
sample do not confer a more rapid rate of cognitive or functional decline.
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Neurotrophins function in neuronal development and maintenance (1, 2). 
Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in 
modulation of episodic memory that occurs in the hippocampus (3-6). It is 
believed that disruption of BDNF may lead to learning and memory deficits (4, 6-
13).  Consequently, the BDNF gene is of interest to researchers investigating 
neurodegenerative disease and cognitive impairment.  
Decreased levels of BDNF mRNA have been observed in brains of 
patients with Alzheimer’s disease (AD) in the parietal cortex (14) and 
hippocampus (15). Evidence also suggests that serum levels of BDNF reflect 
severity of AD, correlating with Mini-Mental State Examination (MMSE) scores 
(16). Measurement of serum BDNF levels in patients with vascular dementia does 
not demonstrate the decrease observed in AD (17). Donepezil, an 
acetylcholinesterase inhibitor with demonstrated cognitive and functional benefits 
for patients with AD, has been found to increase BDNF serum concentrations in 
patients to the level of healthy controls (18). The specific molecular mechanism 
linking acetylcholinesterase and BDNF, however, has not been elucidated.  
Because of the increasing evidence that BDNF may play a role in AD, 
polymorphisms of this gene are being studied to understand better the 
contribution of genetics to this complex condition. 
Geneticists have recently identified several polymorphisms of BDNF:  
C270T, val66met (G196A), and G-712A. Previous research into the role of these 
polymorphisms in the pathogenesis of AD has been conflicting. The T allele of 
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the C270T polymorphism has been identified in several studies to be associated 
with AD (19-22) as well as early-onset AD in patients lacking the apolipoprotein 
E (ApoE) ε4 allele, an established risk factor for AD (23). However, other studies 
found no association (24-29).  
Although the majority of studies examining val66met have found no 
association with AD (20, 25, 27-36), at least two studies have suggested higher 
frequencies of the val allele among patients with AD (19, 37). Additionally, 
val66met has been associated with memory performance, in which patients 
carrying the met allele demonstrate poorer episodic memory (38-40). 
The G-712A allele was recently identified by our group (29) and was not 
found to have an association with AD. 
Regardless of whether BDNF polymorphisms play a direct role in 
predisposing patients to develop AD, the role of this gene in modulating learning 
and memory suggests that it may influence the rate of progression and associated 
symptoms of this disease. The clinical presentation of AD is heterogeneous, 
involving not only memory deficits but also an array of neuropsychiatric 
comorbidities that may or may not present in a particular patient. Several 
investigators have suggested that distinct phenotypes may be evident in cases 
where AD is comorbid with psychosis (41-44) or with major depressive disorder 
(45-47), as compared to AD cases in which those conditions are absent.  
BDNF polymorphisms have already been investigated with respect to 
some of these neuropsychiatric conditions in patients without AD. Extensive 
literature exists evaluating the role of BDNF gene variants in schizophrenia, for 
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which the clinical presentation is largely characterized by psychotic symptoms of 
hallucinations and delusions. It has been reported that the val allele is associated 
with schizophrenia (48), although the met/met genotype has a significantly lower 
age of schizophrenia onset than val/val (49). There is also evidence for 
preferential inheritance of the val allele among patients with psychosis and 
schizophrenia spectrum disorder (50). The C270T-T allele has been documented 
in higher frequency among patients with schizophrenia than healthy controls (51, 
52). However, multiple studies suggest that BDNF polymorphisms have no 
association with schizophrenia (29, 53-55). Other variables have been studied in 
patient populations with schizophrenia to evaluate the effect of BDNF gene 
variants, and it has been observed that val homozygotes have higher scores of 
logical memory than met/val or met/met counterparts (56).  Among patients with 
schizophrenia, those who were classified as catatonic had lower average serum 
BDNF than those who were paranoid or residual (57). 
The association between BDNF and major depressive disorder (MDD) has 
also been studied. It has been reported that in a Chinese population there is an 
excess of the met allele of val66met among geriatric patients with depression 
(58). Additionally, low plasma levels of BDNF have been associated with MDD 
(59) and suicidal behavior in MDD (60). Concordantly, mouse models suggest 
that increased BDNF signaling has an antidepressant-like effect (61), and there is 
an increase in BDNF immunoreactivity in post-mortem tissue of patients treated 
with antidepressant drugs (62).  A recent investigation of depression in AD found 
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an association between the met allele and depressive symptoms in these patients 
(63). 
Research into the association of BDNF with other neuropsychiatric 
conditions has included studies of anxiety, panic disorder, affective disorders, 
post-traumatic stress disorder (PTSD), substance dependence, and general 
neurocognitive dysfunction. It has been demonstrated that val homozygotes have 
higher levels of anxiety than other val66met genotypes (64), and patients with 
panic disorder who have lower levels of serum BDNF have poorer response to 
cognitive behavioral therapy (65). No associations were observed between G-
712A, C270T, or val66met polymorphisms and affective disorder or PTSD, 
although a slight association was discovered between G-712A and substance 
dependence (29). Additionally, among patients with systemic lupus 
erythematosus, the met allele of val66met was associated with better cognitive 
functioning in psychomotor and motor domains (66). 
 
Statement of Purpose, Specific Hypothesis, and Specific Aims 
Patients with AD present with a vast array of neuropsychiatric 
comorbidities in addition to cognitive and functional impairment, with little 
evidence currently in the literature to help predict why there is such variability in 
these phenotypes among the AD patient population. Having observed discrepant 
reports in the literature regarding the role of BDNF in AD and separately in other 
neuropsychiatric conditions, the purpose of this investigation is to evaluate the 
effect of BDNF polymorphisms on cognitive, functional, and behavioral 
           
 
5
symptoms in AD. We hypothesized that val66met met homozygotes would have 
an earlier age of onset and lower educational attainment than other genotypes 
based on the multiple studies suggesting the met allele is associated with poorer 
memory performance(38-40).  We also hypothesized that psychotic symptoms, 
including hallucinations and delusions, would be more highly associated with the 
C270T-T allele based on studies in which this allele was more common among 
patients with schizophrenia (51, 52).  Our study was conducted with the aim to 
provide insight into the specific role of BDNF in AD, and more broadly to 




 The study sample comprised 341 patients with probable AD (67) who 
enrolled in a study of the genetics of AD and were initially evaluated in the Yale 
Alzheimer’s Disease Research Unit (ADRU). Most of these patients participated 
in a variety of other research protocols permitting the accumulation of 
longitudinal cognitive and functional data. Nineteen of these patients have 
subsequently died and had autopsy confirming definite AD (68). The 
demographics and clinical characteristics of patients are displayed in Table 1. The 
racial composition of the sample was: European-American (n=343; 97.7%), 
African-American (n=6; 1.7%), and Hispanic (n=2; 0.57%). 
All patients underwent a comprehensive evaluation by a research 
physician and ancillary staff, including cognitive assessment, medical history, 
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physical and neurological examinations, serum chemistries, thyroid function 
studies, complete blood count, B12, folate, VDRL, urinalysis, electrocardiogram, 
and brain MRI or CT scan. Subjects were excluded for any neurological or 
medical disorder (other than AD) that could produce cognitive deterioration or for 
significant psychiatric illness, alcohol, or substance abuse. Research protocols in 
which subjects participated following their initial evaluation included 
investigational therapeutic trials, neuroimaging studies, and neuropsychological 
studies. Some investigational and clinically prescribed AD treatments received by 
subjects—in particular acetylcholinesterase inhibitors, high-dose vitamin E (≥ 400 
IU daily), and psychotropic drugs—may potentially have impacted behavioral 
variables analyzed in this study. These treatments were assumed to be 
independently distributed with regard to BDNF genotype; however, this 
assumption was also tested statistically (see below). 
 Family history of AD was assessed using the Alzheimer Dementia Risk 
Questionnaire (69) and the Dementia Questionnaire (70) through extensive 
caregiver interview.  Family history was considered positive if at least one first-
degree relative met criteria for primary degenerative dementia.  Caregiver 
interview was also used in conjunction with review of medical records to 
approximate the onset date of AD, estimated to the month of which the earliest 
definite symptom was noticed. All subjects (or their responsible next of kin) 
provided written informed consent and were studied under a protocol approved by 
the Yale Human Investigation Committee. 
 




Subjects were evaluated using a number of cognitive, functional, and 
neuropsychiatric tests and rating scales at the time of initial presentation (see 
Tables 2 and 4). Several of these measures were repeated longitudinally, at 
varying frequencies, depending on the different requirements of the research 
protocols in which subjects subsequently participated. Many subjects enrolled in 
multiple studies spanning several years.  
 
Cognitive Performance. The cognitive performance of subjects was 
measured using the Mini-Mental State Examination (MMSE) (71) and the 
cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-Cog) 
(72). The MMSE evaluates cognition on a scale of 0 (maximal impairment) to 30 
(no impairment) through tests of memory, orientation, and praxis. The ADAS-
Cog is a neuropsychological battery that targets specific domains of cognition 
including memory, orientation, praxis, and language. The ADAS-Cog is much 
more sensitive than other testing, with a range of scores from 0 to 70 for which 
higher scores indicate greater cognitive impairment.  This battery is frequently 
employed to measure efficacy of treatment in drug trials and has been shown to be 
a reliable predictor of cognitive decline in patients with probable AD (73, 74).  Of 
these measures, the medical student author performed approximately 150 MMSE 
evaluations and 40 ADAS-Cog evaluations.  The remainder was completed by 
ancillary staff at the ADRU. 
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Functional Performance. The functional capacity of subjects in activities 
of daily living was assessed through caregiver interview using both the 
Instrumental Activities of Daily Living (IADL) questionnaire (75) and the 
Alzheimer’s Disease Cooperative Study-Activities of Daily Living inventory 
(ADCS-ADL) (76). The IADL was performed only once at baseline (and 
therefore included in retrospective but not prospective analyses) and evaluated 
everyday functioning along eight domains: using the telephone, shopping, food 
preparation, housekeeping, laundry, transportation, handling medications, and 
finances (75). A score of 1 for a given domain indicated no impairment and 0 
indicated inability to complete that task. Since not all domains were valid for all 
subjects (e.g. men who never did laundry before AD onset), the IADL score was 
calculated as the sum of individual activity scores divided by the total possible 
valid points for that subject. The ADCS-ADL provides a comprehensive 
assessment of ADL performance across 28 functional domains and is scored from 
0 (maximal impairment) to 78 (no impairment) (76). Use of these inventories 
previously was described by our group in a study of ApoE genotype and 
functional decline (77).  Of these evaluations, approximately 35 IADLs were 
completed by the medical student author.  The remainder of these exams was 
performed routinely by research staff at the ADRU. 
 
Neuropsychiatric symptoms. All subjects were evaluated for behavioral 
and psychological symptoms using the Neuropsychiatric Inventory (NPI), a 
structured interview that assessed the frequency and severity of these symptoms 
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(78). Using scripted questions, a caregiver was asked whether the patient’s 
behavior had changed after the onset of dementia and whether the altered 
behavior had been present during the month preceding the evaluation. This format 
therefore distinguished between psychiatric symptoms that may have been present 
before the onset of dementia, and those that emerged during the disease process. 
The NPI assessed the following behavioral domains: delusions, hallucinations, 
agitation, depression, anxiety, elation, apathy, disinhibition, irritability, aberrant 
motor behavior, sleep disturbances and eating disturbances. Specific follow-up 
questions were used to confirm the presence of symptoms that were reported 
positive. For each domain in which symptoms were confirmed, the caregiver was 
asked to score the frequency with which symptoms occurred as: occasionally (1), 
often (2), frequently (3) or very frequently (4). The caregiver was asked also to 
score the severity of disturbances as: mild (1), moderate (2) or marked (3). 
Domains absent of disturbances were scored as 0. The product of the frequency 
and severity score was determined for each positive item (range=1-12), and the 
sum of all item scores yielded the total NPI score. Possible scores ranged from 0 
(no behavioral disturbances) to 144 (all behavioral disturbances maximally 
present).  Use of the NPI was described previously by our group in a study of 
ApoE genotype association with psychotic symptoms (79).  Of these NPI 
evaluations, approximately 35 were completed by the medical student author.  
The remainder was performed routinely by research staff at the ADRU. 
Of the cognitive, functional, and neuropsychiatric measures, the MMSE 
was performed on the entire sample (N = 341), whereas all other measures were 
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available for only certain subsets of the subject population (as detailed in Tables 2 
and 4). All subject data were obtained by trained raters who were unaware of the 
subjects’ BDNF genotypes. 
 
Determination of BDNF genotypes 
BDNF genotype determination was performed at the VA Connecticut 
Healthcare System, West Haven, CT, by Dr. Joel Gelernter and colleagues.  As 
previously described by our group (29), BDNF sequence information was 
obtained through the public "GoldenPath" database (http://genome.ucsc.edu). 
Fifteen pairs of primers were designed to amplify part of the 5’ region, the 
noncoding exon I, and the only coding exon V of the BDNF gene (29). Amplicons 
derived from 16-48 DNA samples of the above patients with various diagnoses 
and healthy controls were scanned using denaturing high performance liquid 
chromatography (dHPLC). A dHPLC mutation screen of the BDNF gene was 
carried out by using the “Wave” DNA Fragment Analysis System (Transgenomic, 
USA). Five-15 µl of the polymerase chain reaction (PCR) mixture was loaded on 
a “DNASep” cartridge using a linear acetonitrile gradient in a triethylamine buffer 
at a constant flow rate of 0.9 ml/min. The gradient was created by mixing the 
eluents A (0.1 M triethylamine) and B (0.1 M triethylamine and 25% Acetonitrile) 
at concentrations determined by the Transgenomic “Wavemaker” software. 
Samples that showed mobility shifts were sequenced using cycling sequencing 
and fluorescently labeled dideoxynucleotides on an ABI 3100 Genetic Analyzer 
(Applied Biosystems). A newly identified SNP, G-712A (29), and two previously 
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reported SNPs, C270T (21) and Val66Met (80), were genotyped in patients with 
AD by PCR and restriction fragment length polymorphism (PCR-RFLP) analysis. 
Primer pairs and PCR conditions for genotyping the three BDNF SNPs have been 
previously summarized (29). 
 
Statistical Analysis 
Analyses of the val66met polymorphism involved three-group 
comparisons (val/val, val/met, met/met). However, the C270T and G-712A 
polymorphisms were studied using two-group comparisons between carriers and 
non-carriers of the less frequent allele, given the scarcity of homozygotes for the 
C270T T-allele (n = 3) and the G-712A A-allele (n = 2). Subject characteristics 
(including demographics, disease characteristics, and concomitant therapies) were 
compared across gene dose groups using Student’s t-test or analysis of variance 
(ANOVA) for continuous variables or chi-square analysis for dichotomous 
variables. 
The effect of each BDNF polymorphism on the rate of AD progression 
was analyzed using both retrospective and prospective techniques similar to those 
employed in our previous study of ApoE ε4 (77). The retrospective analyses 
examined cross-sectional cognitive (MMSE, ADAS-Cog) and functional (IADL, 
ADCS-ADL) data obtained at each subject’s initial visit, while controlling for the 
duration of symptoms by analysis of covariance (ANCOVA). Although disease 
duration was the essential covariate in all retrospective analyses, age, sex, and 
educational attainment were also included as covariates in the ANCOVA models. 
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Prospective analyses of disease progression were also conducted for the 
MMSE, ADAS-Cog, and ADCS-ADL for all subjects who had at least two 
observations spanning at least six months of research participation. For these 
analyses, an annualized rate of change in performance on each scale was 
calculated by least-squares regression, using all available measurements for each 
subject. Rates of change were compared across BDNF genotype groups by 
ANCOVA, controlling for age, sex, and education. 
 
Behavioral Outcomes. We derived an NPI-Psychosis score for each 
subject by summing the domain scores for the delusions and hallucinations 
sections of the full NPI. Subjects with an NPI-Psychosis score of 1 or greater 
were coded positively for the AD+Psychosis phenotype. These criteria reflect our 
conception of an AD “phenotype” as an identifiable condition in which psychotic 
disturbances occur with substantial frequency and/or severity. Each BDNF 
genotype was analyzed as a potential predictor of the AD+Psychosis phenotype 
using separate logistic regression models. In the AD+Psychosis model, MMSE 
score and ApoE ε4 genotype were included as covariates because our previous 
study found them significant, independent predictors of this phenotype (79).  
An exploratory analysis of the association between BDNF and other 
behavioral disturbances in AD was conducted, using the rest of the data from the 
NPI. It was observed that the distribution of total NPI scores did not satisfy the 
assumption of normality because of a “floor effect” – many subjects scored zero. 
Nonparametric analyses (Mann-Whitney U or Kruskal-Wallis H) were employed 
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to determine if specific genotype groups differed in total NPI score. Logistic 
regression analyses were performed to explore whether BDNF genotype predicted 
zero vs. nonzero domain scores on each item of the NPI (e.g. irritability, anxiety). 
The literature does not provide a clear indication of the appropriate covariates for 
each item of the NPI. Covariates chosen included sex, age at time of testing, 
MMSE score, and education level. This analysis makes no assumptions about the 
nature of AD phenotypes; rather, it explores whether BDNF genotype is related at 
all to the appearance of specific behavioral disturbances within an AD population. 
 
Results 
 The genotypic distribution of these three SNPs—val66met, C270T, and G-




Table 1 presents the demographic and clinical characteristics of the entire 
sample, as well as each genotype group. Within the AD sample, val66met 
genotypes were available for n = 332 subjects; C270T genotypes for n = 332 
subjects; and G-712A genotypes for n = 310 subjects. The two planned 
comparisons of educational attainment and age of onset among val66met groups 
were analyzed. There was a significant effect of val66met genotype on 
educational attainment (F = 7.42; df = 2, 329; P = .00070) (See Figure 1). Post-
hoc Tukey test revealed that the met/met homozygote group had significantly 
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lower education than both the val/met heterozygotes (P = .00062) and the val/val 
homozygotes (P = .0068). However, the val/met heterozygote and val/val 
homozygote groups did not differ from each other (P = .13). There was no 
significant effect of either C270T or G-712A genotype on educational attainment. 
There was no significant effect of any of the three polymorphisms with regard to 
age of disease onset. 
Few significant demographic differences were observed across genotype 
groups.  In our sample, carriers of the A712 allele were disproportionately female 
(χ2 = 4.57, df = 1, P = .032).  Treatment history for acetylcholinesterase 
inhibitors, anti-psychotics, antidepressants and high-dose vitamin E was 
distributed independently with respect to genotype. The only exception was that 
our sample of met/met was significantly more likely than val/val or val/met 
groups to have been taking acetylcholinesterase inhibitors at the time of study 
assessment (χ2 = 6.21, df = 1, P = 0.045). Apart from these observations, all 
genotype groups were well matched for demographic and disease characteristics. 
 
Retrospective Analysis of Cognitive and Functional Progression 
Table 2 presents a summary of the retrospective analyses of cognitive and 
functional progression in AD patients. It specifically contains the baseline 
cognitive and functional data according to BDNF genotypes. 
 
Val66met 
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MMSE performance was analyzed in the overall sample of n = 332 
subjects. Gene dose groups did not differ significantly in MMSE performance (F 
= 0.65; df = 2, 325; P = .52), controlling for disease duration, age, sex, and 
education.   
ADAS-Cog performance was analyzed in a sub-sample of n = 274 
subjects. The demographic profile of this sub-sample and all others analyzed 
below did not differ from that of the overall sample characterized in Table 1. 
Gene dose groups did not differ significantly in ADAS-Cog performance (F = 
0.75; df = 2, 267; P = .47), controlling for disease duration, age, sex, and 
education. 
IADL performance was analyzed in a sub-sample of n = 320 subjects. 
Gene dose groups did not differ significantly in IADL performance (F = 0.01; df 
= 2, 313; P = .99), controlling for disease duration, age, sex, and education.   
ADCS-ADL performance was analyzed in a sub-sample of n = 165 
subjects. Gene dose groups did not differ significantly in ADCS-ADL 
performance (F = 0.84; df = 2, 158; P = .43), controlling for disease duration, age, 
sex, and education. 
 
C270T 
MMSE performance was analyzed in the overall sample of n = 332 
subjects. Gene dose groups did not differ significantly in MMSE performance (F 
= 0.01; df = 1, 326; P = .93), controlling for disease duration, age, sex, and 
education. 
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ADAS-Cog performance was analyzed in a sub-sample of n = 275 
subjects. The demographic profile of this sub-sample and all others analyzed 
below did not differ from that of the overall sample characterized in Table 1. 
Gene dose groups did not differ significantly in ADAS-Cog performance (F = 
0.04; df = 1, 269; P = .83), controlling for disease duration, age, sex, and 
education. 
IADL performance was analyzed in a sub-sample of n = 320 subjects. 
Gene dose groups did not differ significantly in IADL performance (F = 0.60; df 
= 1, 314; P = .44), controlling for disease duration, age, sex, and education. 
ADCS-ADL performance was analyzed in a sub-sample of n = 165 
subjects. Gene dose groups did not differ significantly in ADCS-ADL 
performance (F = 0.40; df = 1, 159; P = .53), controlling for disease duration, age, 
sex, and education. 
 
G-712A 
MMSE performance was analyzed in the overall sample of N = 310 
subjects. Gene dose groups did not differ significantly in MMSE performance (F 
= 0.12; df = 1, 304; P = .73), controlling for disease duration, age, sex, and 
education. 
ADAS-Cog performance was analyzed in a sub-sample of n = 261 
subjects. The demographic profile of this sub-sample and all others analyzed 
below did not differ from that of the overall sample characterized in Table 1. 
Gene dose groups did not differ significantly in ADAS-Cog performance (F = 
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0.02; df = 1, 255; P = .90), controlling for disease duration, age, sex, and 
education. 
IADL performance was analyzed in a sub-sample of n = 299 subjects. 
Gene dose groups did not differ significantly in IADL performance (F = 0.78; df 
= 1, 293; P = .38), controlling for disease duration, age, sex, and education. 
ADCS-ADL performance was analyzed in a sub-sample of n = 154 
subjects. Gene dose groups did not differ significantly in ADCS-ADL 
performance (F = 1.15; df = 1, 148; P = .29), controlling for disease duration, age, 
sex, and education. 
 
Prospective Analysis of Cognitive and Functional Progression 
Table 3 presents a summary of the prospective analyses of cognitive and 
functional progression in AD patients. It specifically contains the annualized rates 
of change for cognitive and functional measures according to BDNF genotypes. 
 
Val66met 
Annualized rate of change in MMSE performance was analyzed in a sub-
sample of n = 215 subjects. Subjects received an average of 6.7 assessments 
(range = 3-18) spanning 1.8 years of follow-up (range = 0.5-6.4). The rate of 
MMSE change did not differ significantly across gene dose groups (F = .00; df = 
2, 209; P = 1.00), controlling for age, sex, and education. 
Annualized rate of change in ADAS-Cog performance was analyzed in a 
sub-sample of n = 179 subjects. Subjects received an average of 9.4 assessments 
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(range = 3-25) spanning 1.6 years of follow-up (range = 0.5-5.8). The rate of 
ADAS-Cog change did not differ significantly across gene dose groups (F = .04; 
df = 2, 173; P = .97), controlling for age, sex, and education. 
Annualized rate of change in ADCS-ADL performance was analyzed in a 
sub-sample of n = 156 subjects. Subjects received an average of 7.1 assessments 
(range = 3-18) spanning 1.4 years of follow-up (range = 0.5-4.9). The rate of 
ADCS-ADL change did not differ significantly across gene dose groups (F = .41; 
df = 2, 150; P = .67), controlling for age, sex, and education. 
 
C270T 
Annualized rate of change in MMSE performance was analyzed in a sub-
sample of n = 213 subjects. Subjects received an average of 6.7 assessments 
(range = 3-18) spanning 1.8 years of follow-up (range = 0.5-6.4). The rate of 
MMSE change did not differ significantly across gene dose groups (F = .69; df = 
1, 208; P = .41), controlling for age, sex, and education. 
Annualized rate of change in ADAS-Cog performance was analyzed in a 
sub-sample of n = 179 subjects. Subjects received an average of 9.4 assessments 
(range = 3-25) spanning 1.6 years of follow-up (range = 0.5-5.8). The rate of 
ADAS-Cog change did not differ significantly across gene dose groups (F = 2.47; 
df = 1, 174; P = .12), controlling for age, sex, and education. 
Annualized rate of change in ADCS-ADL performance was analyzed in a 
sub-sample of n = 154 subjects. Subjects received an average of 7.1 assessments 
(range = 3-18) spanning 1.4 years of follow-up (range = 0.5-4.9). The rate of 
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ADCS-ADL change did not differ significantly across gene dose groups (F = .01; 
df = 1, 149; P = .94), controlling for age, sex, and education. 
 
G-712A 
Annualized rate of change in MMSE performance was analyzed in a sub-
sample of n = 198 subjects. Subjects received an average of 6.7 assessments 
(range = 3-18) spanning 1.8 years of follow-up (range = 0.5-6.4). The rate of 
MMSE change did not differ significantly across gene dose groups (F = 1.33; df = 
1, 193; P = .25), controlling for age, sex, and education. 
Annualized rate of change in ADAS-Cog performance was analyzed in a 
sub-sample of n = 171 subjects. Subjects received an average of 9.4 assessments 
(range = 3-25) spanning 1.6 years of follow-up (range = 0.5-5.8). The rate of 
ADAS-Cog change did not differ significantly across gene dose groups (F = 3.24; 
df = 1, 166; P = .07), controlling for age, sex, and education. 
Annualized rate of change in ADCS-ADL performance was analyzed in a 
sub-sample of n = 145 subjects. Subjects received an average of 7.1 assessments 
(range = 3-18) spanning 1.4 years of follow-up (range = 0.5-4.9). The rate of 
ADCS-ADL change did not differ significantly across gene dose groups (F = 
0.83; df = 1, 140; P = .40), controlling for age, sex, and education. 
 
Analysis of Behavioral Symptoms 
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 Table 4 summarizes the behavioral outcomes measured by the NPI, 
including percentage of subjects with each neuropsychiatric symptom as well as 
odds ratios for these symptoms by genotype. 
NPI data were available for n = 248 subjects in our AD sample. Of these, 
val66met and C270T genotypes were available for n = 241 subjects, and G-712A 
genotypes were available for n = 222. No significant differences in Total NPI 
score across genotype groups were found by a Kruskal-Wallis H test for val66met 
(χ2 = 1.61, df = 2, N = 241, p = .45). Carriers of the C270T-T allele had a higher 
mean rank for Total NPI score as revealed by Mann-Whitney U test, indicating a 
greater prevalence of behavioral disturbances in that group (Z = -2.11, N = 241, p 
= .035). G-712A genotype groups did not differ in Total NPI score (Z = -1.66, N = 
222, p = .098). 
Our selection criterion identified n = 86 subjects with the Psychosis ≥1 
phenotype (n = 164 subjects without). This phenotype was not associated with 
genotype for val66met (OR = 2.94, 95% CI = [0.58, 15.04]), C270T (OR = 2.23, 
95% CI = [0.88-5.63]), or G-712A (OR = 1.89, 95% CI = [0.71-4.97]).  
In our exploratory logistic regression models, neither val66met nor G-
712A genotype was associated with the appearance of behavioral disturbances on 
any NPI domain. The C270T-T allele was associated with the presence of 
hallucinations (OR = 3.25, 95% CI = [1.22-8.62], p = .018) but not with 
disturbances in any other specific NPI domain. 
 
 




This is the first study to evaluate the role of three BDNF polymorphisms 
with respect to cognitive and functional progression and behavioral symptoms in 
AD. Analysis of val66met found met homozygotes to have significantly lower 
educational attainment relative to val/met and val/val genotypes. Although 
retrospective and prospective analyses of cognitive and functional progression 
revealed no association with the val66met, C270T, or G-712A polymorphisms, 
analysis of behavioral symptoms demonstrated an association between the 
C270T-T allele and presence of hallucinations as well as increased total NPI 
score.  
The most striking finding of this study was the highly significant effect of 
val66met genotype on educational attainment, as we hypothesized, demonstrating 
an association between met homozygosity and fewer years of education. Limited 
research has been conducted examining the relationship between educational 
attainment and BDNF genotype. Chuu et al. demonstrated within an AD 
population a trend towards lower educational attainment among met homozygotes 
(13.2 years vs. 14.0 years for val/val and 14.3 years for val/met genotypes), 
consistent with our finding, although this difference was not statistically 
significant (81). This trend was also true of a recent study by Borroni et al. in 
which met homozygotes had 0.99 fewer years of education than val homozygotes 
and 0.91 fewer years than heterozygotes (63). Taylor et al. observed no difference 
in education level between val homozygotes and met carriers among patients with 
depression and healthy controls; met homozygotes were not distinguished from 
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heterozygotes in this study due to small sample size (82). This is consistent with 
our finding inasmuch as our group demonstrated a significant difference only 
between met homozygotes and the other genotypes. Egan et al. demonstrated no 
significant effect of val66met on educational attainment among patients with 
schizophrenia, their siblings, or healthy controls; however, met homozygotes 
trended toward more years of education—17.7 years—when compared with val 
homozygotes (16.2 years) and heterozygotes (16.7 years) (38). 
The discrepancies among these studies may be explained in part by the 
presence of AD among patients in our sample and in the Chuu et al. and Borroni 
et al. studies. Low level of educational attainment has been described as a risk 
factor for AD (83-90). It has been demonstrated that patients with higher 
educational attainment perform better on neuropsychological testing and are less 
likely to meet criteria for dementia when at the same neuropathological stage of 
AD as less-educated counterparts (91, 92). A systematic review of studies of 
“cognitive reserve” and risk of dementia found a 46% decreased risk of AD 
among patients with a high brain reserve (that is, those with “complex mental 
activity across the lifespan”) (93). Whether education provides a cognitive reserve 
to protect individuals from developing AD, or more highly educated people 
perform better on the neuropsychological testing employed to diagnose dementia, 
is a point of debate (90). It is possible that the effect of genotype on educational 
attainment observed in our study might be a consequence of the sample of AD 
patients, as they may have had a lower baseline cognitive reserve than a sample of 
non-AD counterparts.  
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Although the relationship of BDNF polymorphisms and educational 
attainment has not been studied in detail, researchers have examined the 
association of BDNF polymorphisms with memory performance. Several studies 
suggest that met carriers exhibit impaired episodic memory relative to val 
homozygotes (38-40). A second interpretation of our finding might be that 
patients who are met homozygotes (or, taking results of prior studies into 
consideration, met carriers, as our study may not have been sensitive enough to 
detect significant differences in educational attainment among heterozygotes) 
have impaired memory ability, consequently may have more difficulty with 
academic performance, and ultimately may have lower overall educational 
attainment. In conjunction with the cognitive reserve hypothesis, it would follow 
that if lower educational attainment is associated with risk of AD, one would 
expect met carriers to demonstrate higher rates of AD than val homozygotes. 
However, the vast majority of studies examining risk of AD with the val66met 
polymorphism demonstrate no association (20, 25-28, 30-34), or association of 
the val allele with AD (19, 37).  Additionally, one would expect that met carriers 
would have a lower age of onset, as we hypothesized, because they lack the 
protective factor of cognitive reserve.  However, our study suggests that there is 
no association, and this is in agreement with other studies (30, 94). 
The other significant demographic findings of this study—that met 
homozygotes were more likely to be taking acetylcholinesterase inhibitors at the 
time of assessment, and that significantly more women carried the A712 allele—
are more challenging to interpret.  The significantly higher use of 
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acetylcholinesterase inhibitors may be related to the findings that the met allele 
predisposes to impaired episodic memory relative to other genotype groups (38-
40): a drop in memory performance from a lower baseline may incite these 
patients to seek medication at an earlier stage than counterparts who declined 
from a higher baseline and therefore remain more functional.  Because so little is 
known about the G-712A polymorphism or its effects physiologically, reasons for 
women to carry the A712 allele are unclear and more research should be 
conducted to determine whether this relationship holds in non-AD samples. 
The finding that val66met, C270T, and G-712A polymorphisms are 
unrelated to rate of cognitive decline in AD is consistent with a previous study in 
which val66met was found to have no association with rate of change of MMSE 
score (81). While Chuu et al. determined rate of change by sequential MMSE 
scores, our study determined rate of change both this way and retrospectively, 
using approximate onset date of AD to estimate disease duration at time of 
testing. Cognitive decline was additionally measured by ADAS-Cog scores, 
following methods to evaluate rate of cognitive decline previously employed by 
our group (77) and others (95). To our knowledge, this is the only study to offer 
both retrospective and prospective analyses of cognitive decline as well as to 
examine ADAS-Cog scores in relation to these BDNF polymorphisms. Of note,  
this methodology follows our previous study of ApoE, in which no relationship 
was established between rate of cognitive decline and ApoE, corroborating data 
from several other groups (96-109), but in contrast to data from three studies 
suggesting ε4 accelerates rate of cognitive decline (95, 110, 111). It should be 
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clarified that no association between ApoE and BDNF genotypes has been 
established (20, 21, 25, 31, 33-35, 37), although it has been suggested that the 
C270T-T allele is more common among individuals lacking ε4 (19), and the risk 
of AD conferred by the C270T-T allele is stronger in patients who do not carry ε4 
(23).  
No studies were identified in the literature examining rate of functional 
decline with respect to BDNF polymorphisms. Borroni et al. demonstrated no 
association of val66met genotype with cross-sectional IADL score for patients 
with AD, but this single measurement did not estimate rate of decline (63). 
The association of the C270T-T allele and increased total NPI score is 
difficult to interpret given the variety of psychiatric domains evaluated by this 
scale.  We hypothesized that psychotic symptoms would be more prevalent in this 
genotype group given previous association studies with the polymorphism and 
schizophrenia.  However, only “hallucinations” showed a significant association 
with the allele; no association with “psychosis” was established when 
hallucinations and delusions were considered together. This was of interest to our 
group given our previous finding of an association between ApoE ε4 and 
psychotic symptoms in AD, particularly from an association with delusions (79). 
The differences between the BDNF and ApoE studies again reinforce that these 
are distinct genotypes whose effects are accrued independently from one another.  
Several studies in the literature have examined the relationship between BDNF 
polymorphisms and schizophrenia. Consistent with our finding, the C270T-T 
allele has been documented in higher frequency among patients with 
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schizophrenia than healthy controls (51, 52). Our finding that hallucinations were 
not associated with val66met genotype is consistent with the findings of Borroni 
et al., who found no association of psychotic symptoms in AD patients 
specifically with this allele (63). Although psychotic symptoms were not 
associated with val66met in our study, it has been reported that the val allele is 
associated with schizophrenia (48). There is also evidence for preferential 
inheritance of the val allele among patients with psychosis and schizophrenia 
spectrum disorder (50). Multiple studies, however, including one from our own 
group, suggest that BDNF polymorphisms have no association with schizophrenia 
(29, 53-55). Conflicting data among these studies emphasizes the need for further 
examination of the role of BDNF polymorphisms among patients with psychotic 
symptoms, both those with AD and those with schizophrenia. 
Our study did not find an association of val66met genotype with total NPI 
score or sub-categories of the NPI.  This disputes the recent investigation by 
Borroni et al. that demonstrated a significant association between the met allele 
and increased total NPI score as well as NPI depression and apathy scores (63).  
One possibility for this discrepancy is that the Borroni study examined a cohort of 
depressed AD patients that may have contributed a disproportionately large 
number of patients with neuropsychiatric disturbances to the sample.  Our sample 
included 83 patients in a sample of 241 with positive depressive symptoms on the 
NPI, in contrast with 93 clinically depressed patients in a sample of 264 in the 
Borroni study.  The key difference is that “depressive symptoms” observed on the 
NPI do not necessarily render a diagnosis of depression, and therefore the patients 
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in the Borroni sample likely had higher ratings of frequency, severity, and distress 
than our patients.  Larger numbers of more severely depressed patients may have 
made this genetic relationship for depression significant, and apathy is a 
characteristic of depression that consequently became statistically significant as 
well. 
A notable limitation of this study is selection bias:  enrolled subjects were 
recruited from other research protocols at an academic medical center. Many of 
these protocols were investigational drug trials, which may have inadvertently 
changed the course of AD progression for our prospective and retrospective 
analyses. Most of these experimental treatments were not found to impact the 
course of AD, however, and any small effect was likely distributed randomly with 
respect to genotype. Ethnically, the patients were overwhelmingly Caucasian. 
None of the patients were institutionalized at the time of participation. Further 
research should be conducted before results of this study may be elaborated to 
other groups. Another significant limitation is reliance upon caregiver interview, 
which introduces recall bias both in estimating date of disease onset for 
retrospective analyses and in obtaining data for the NPI (78). Nonetheless, 
relatives’ prospective and retrospective ratings have been found to be in close 
agreement, particularly when the patient still resides in the community (112). 
This investigation finds its place in the new era of psychiatric research, 
that of the genetics of mental illness. On the road to this understanding, the 
complexities of these conditions emerge:  a particular gene may be associated 
with only a small part of a disease presentation.  In the case of this study, the 
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effects of a single nucleotide substitution become apparent:  the C270T-T allele 
contributes to hallucinations and overall neuropsychiatric symptomatology in 
patients with AD.  A nucleotide substitution in val66met yields a new amino acid, 
and that met allele in turn may predict an individual’s ultimate educational 
attainment.  It is through an aggregate of these individual changes that particular 
phenotypes of psychiatric illnesses evolve.  “Dementia” is no longer dementia 
alone, but dementia with psychosis, dementia with depression, dementia with 
agitation; “depression” becomes depression with psychotic features, depression 
with anxiety, depression with agitation, and so on. 
The clinical applicability of genotyping patients is limited at this stage of 
understanding.  However, once the genetic basis of psychiatric illness is better 
elucidated, it has the potential to revolutionize the way patients are treated.  In the 
case of patients with the C270T-T allele who develop AD, if it is known that these 
patients may be predisposed to develop hallucinations, then caregivers and 
physicians may be more in-tune with this psychotic symptom in the patient and 
consequently may be able to treat the patient from an early manifestation.  This is 
true of other neuropsychiatric comorbidities of AD that may be associated with 
this allele and others as well.  With respect to our finding of lower educational 
attainment in met homozygotes, if this finding holds true universally and not just 
in a sample of AD patients, then theoretically if children were known to be 
genetically disadvantaged to achieve academically, different approaches to 
teaching and learning that rely less on rote memorization and more on integrating 
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ideas and concepts may help a young student to achieve higher levels of 
schooling. 
That stated, the concept of genotyping remains controversial in the public 
eye.  Many at-risk individuals already refuse available genetic tests for heritable 
diseases such as Huntington’s disease, colon cancer, and breast cancer, stating 
they “don’t want to know” if they are at risk.  In the case of AD, neither patients 
with mild cognitive impairment nor healthy adults are routinely screened for well-
established predisposing genetic factors such as the ApoE ε4 allele given that the 
genotype does not guarantee development of the disease and therefore is of 
limited clinical utility.  Some patients worry that discovering a genotype that 
predisposes to illness will also impact health insurance coverage, making plans 
less available and more costly.  However, many individuals are curious to know 
their own health risks, and the idea of “personalized medicine” employing 
techniques such as genotyping is now becoming a reality. 
 Although the findings of this study and others may not lead to immediate 
genotyping of patients with AD for reasons of practicality, genetic association 
studies are helpful in understanding the pathogenesis of the disease. As data is 
gathered throughout the field of genetic psychiatry, the molecular basis of 
psychiatric diseases is better understood. This understanding begins with the 
association, but from there many questions are raised:  what about the protein 
coded by this gene is influencing the patient’s symptomatology?  What makes this 
different from the protein coded by this allele in a healthy subject?  How is this 
different from the protein coded by a different allele in another patient with 
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similar symptomatology?  How can we use the understanding of these proteins to 
develop new therapeutic strategies for our patients?  Can new medications be 
tailored to genotype?  These questions direct the next steps from this 
investigation: to examine BDNF genotype in non-AD samples to evaluate if met 
homozygotes achieve fewer years of schooling; to determine if non-AD age-
matched subjects carrying the C270T-T allele are predisposed to increased 
neuropsychiatric disturbance; to elucidate what molecularly causes BDNF 
expression to decrease in AD, and whether decreased BDNF levels are a cause of 
the disease symptomatology or effect of some other pathogenesis; to continue to 
examine what other genetic factors may influence the variability of AD 
presentation; and to evaluate the role of BDNF as a target for AD therapeutics. 
 
Conclusion 
 This study demonstrates a relationship of the val66met genotype with 
educational attainment in which met homozygotes had significantly fewer years 
of education than either val/met or val/val counterparts.  No association was 
found between cognitive and functional progression and BDNF genotype through 
retrospective and prospective analyses. An association between the C270T-T 
allele and hallucinations as well as overall NPI score was observed. This is the 
first study to exhibit these findings, which should be examined in a more diverse 
pool of subjects before generalizing the results. Additionally, more research 
should be conducted to understand more clearly the pathological link between 
genotype and cognitive, functional, and behavioral outcomes in AD. 











Fig. 1:  Effect of val66met genotype on educational attainment.  Met 
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Table 1. Subject characteristics
Val/Val Val/Met Met/Met C/C T-carrier G/G A-carrier
(n=341) (n =203) (n =117) (n =12) (n =301) (n =31) (n =282) (n =28)
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Demographics
Age 73.8 ±8.4 73.3 ±8.4 74.4 ±8.3 73.9 ±7.4 73.6 ±8.4 73.9 ±8.5 73.7 ±8.4 74.5 ±8.1
Sex (% female)
Education (years) 13.2 ±3.3 13.1 ±3.3 13.8 ±3.2 10.2 ±2.9b 13.2 ±3.4 13.1 ±2.5 13.3 ±3.4 12.8 ±2.2
Disease Characteristics
Onset age 69.3 ±8.3 68.8 ±8.3 70.0 ±8.2 69.6 ±8.2 69.17 ±8.3 69.1 ±8.2 69.3 ±8.3 69.9 ±8.2
Duration (years) 4.5 ±2.0 4.5 ±2.0 4.4 ±2.1 4.3 ±2.2 4.4 ±2.0 4.8 ±1.9 4.4 ±2.0 4.6 ±1.5
Family history (% positive)
ApoE e4 carrier (%)
Cholinesterase inhibitors (% use)
Antipsychotics (% use)
Antidepressants (% use)
Vitamin E (≥400 IU daily) (% use)
Family history was positive if primary degenerative dementia was present in a first-degree relative.
aA-carriers were disproportionately female (χ2=4.57, P=.032)
bMet/Met had significantly lower educational attainment than Val/Met (P=.00062) and Val/Val (P=.0068) (ANCOVA; post hoc Tukey test)
cMet/Met was significantly more likely than Val/Val or Val/Met to be taking cholinesterase inhibitors (χ2=6.21, P=0.045)
77.4% 59.6%62.8% 63.5% 58.1% 61.1% 82.1%a
48.8% 46.0% 54.7% 41.7% 49.5% 35.4% 51.2% 35.7%
83.3%
50.0% 57.5% 48.1%
Concomitant Therapies at Baseline
57.4% 61.4% 52.6% 50.0% 58.3%
35.2% 38.4% 29.1% 58.3%c 35.5% 32.3% 33.3% 35.7%
3.5% 3.9% 3.4% 0.0% 3.3% 6.5% 2.8% 7.1%
17.6% 18.2% 14.5% 41.7% 17.6% 16.1% 16.3% 21.4%
36.1% 34.0% 40.2% 33.3% 38.2% 19.4% 37.2% 21.4%
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Table 2. Cognitive and functional data at baseline
Val/Val Val/Met Met/Met C/C T-carrier G/G A-carrier
(n =341) (n =203) (n =117) (n =12) (n =301) (n =31) (n =282) (n =28)
Variable  Mean SD  Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
n =203 n =117 n =12 n  = 301 n =31 n =282 n =28
MMSE (n =341) 17.2 ±5.5 17.3 ±5.4 17.0 ±5.7 17.8 ±5.9 17.2 ±5.5 17.2 ±4.7 17.2 ±5.6 17.5 ±4.5
n =167 n =97 n =10 n =252 n =23 n =239 n =22
ADAS-Cog (n =282) 27.1 ±12.0 27.1 ±12.4 27.7 ±11.5 24.5 ±11.2 27.2 ±12.1 27.8 ±10.4 27.4 ±12.1 27.9 ±10.8
n =196 n =112 n =12 n =289 n =31 n =271 n =28
IADL (n =329) 0.65 ±0.19 0.65 ±0.19 0.65 ±0.19 0.65 ±0.17 0.65 ±0.19 0.68 ±0.18 0.65 ±0.19 0.68 ±0.17
n =100 n =58 n =7 n =149 n =16 n =141 n =13
ADCS-ADL (n =170) 57.3 ±14.4 57.8 ±13.4 56.0 ±16.6 62.0 ±6.7 57.3 ±14.3 57.0 ±12.7 57.4 ±14.6 59.5 ±10.7
Data displayed are baseline cognitive and functional measures adjusted for disease duration, patient age, sex, and education.  MMSE = 
Mini-Mental State Examination; ADAS-Cog = Alzheimer's Disease Assessment Scale–Cognitive Subscale; IADL = Instrumental Ac
Val66MetAll Subjects C270T G-712A
 
Table 3. Prospective analysis of cognitive and functional data
Val/Val Val/Met Met/Met C/C T-carrier G/G A-carrier
(n =341) (n =203) (n =117) (n =12) (n =301) (n =31) (n =282) (n =28)
Variable Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
n =220 n =135 n =73 n =7 n =197 n =16 n =184 n =14
MMSE annual change -3.12 ±3.70 -3.17 ±3.93 -3.03 ±3.51 -3.34 ±1.60 -3.11 ±3.73 -3.93 ±3.83 -3.04 ±3.83 -4.19 ±3.98
Number of observations 6.8 ±3.5 6.7 ±3.1 6.9 ±4.1 6.4 ±2.7 6.9 ±3.5 5.3 ±2.9 7.0 ±3.6 4.7 ±2.2
Duration of observation (yrs) 1.79 ±1.31 1.73 ±1.246 1.87 ±1.45 1.51 ±0.65 1.82 ±1.34 1.32 ±1.02 1.84 ±1.36 1.14 ±0.75
n =184 n =107 n =66 n =6 n =165 n =14 n =157 n =14
ADAS-Cog annual change* 5.93 ±9.03 6.13 ±10.34 5.83 ±7.18 5.70 ±3.77 5.63 ±8.87 9.53 ±11.18 5.52 ±8.97 9.81 ±11.27
Number of observations 9.4 ±5.1 8.9 ±5.0 10.1 ±5.3 9.7 ±4.4 9.3 ±5.0 10.4 ±7.2 9.5 ±5.0 9.2 ±5.8
Duration of observation (yrs) 1.63 ±1.22 1.51 ±1.23 1.78 ±1.24 1.61 ±0.63 1.63 ±1.22 1.55 ±1.27 1.66 ±1.25 1.36 ±1.07
n =160 n =97 n =53 n =6 n =143 n =11 n =135 n =10
ADCS-ADL annual change -10.37 ±11.17 -10.10 ±10.84 -10.34 ±11.63 -14.12 ±13.03 -10.68 ±11.51 -9.55 ±8.49 -10.34 ±11.59 -12.41 ±10.02
Number of observations 7.1 ±3.2 6.7 ±2.7 7.8 ±4.0 6.7 ±2.1 7.1 ±3.3 5.7 ±1.7 7.2 ±3.4 5.9 ±1.4
Duration of observation (yrs) 1.39 ±1.01 1.30 ±0.89 1.57 ±1.23 1.16 ±0.43 1.40 ±1.04 0.90 ±0.41 1.43 ±1.07 0.90 ±0.34
Data displayed are longitudinal rates of change per year computed by linear regression.
*Rates of ADAS-Cog change are positive because lower scores indicate better performance.
MMSE = Mini-Mental State Examination; ADAS-Cog = Alzheimer's Disease Assessment Scale–Cognitive Subscale;
ADCS-ADL = Alzheimer's Disease Cooperative Study–Activities of Daily Living.
Val66Met C270TAll Subjects G-712A




Table 4. Analysis of neuropsychiatric symptoms
Frequency Val66Met C270T G712A
(n =241) (n =241) (n =222)
NPI Subscore n % OR [95% CI]a OR [95% CI]b OR [95% CI]b
Delusions 76 30.6 0.64 [0.38-1.09] 1.39 [0.54-3.6] 1.44 [0.53-3.91]
Hallucinations 39 15.7 0.73 [0.38-1.40] 3.25 [1.22-8.62]c 2.76 [0.98-7.78]
Aggression 83 33.5 0.68 [0.41-1.13] 2.48 [0.97-6.33] 1.89 [0.70-5.14]
Anxiety 73 29.4 0.95 [0.58-1.55] 1.70 [0.68-4.24] 1.15 [0.41-3.22]
Depression 83 33.5 0.83 [0.51-1.33] 1.47 [0.60-3.64] 1.99 [0.78-5.10]
Elation 18 7.3 * * *
Apathy 95 38.3 0.82 [0.52-1.31] 1.68 [0.69-4.12] 1.55 [0.59-4.02]
Disinhibition 53 21.4 0.86 [0.49-1.50] 1.73 [0.66-4.58] 1.43 [0.47-4.33]
Irritability 80 32.3 0.94 [0.59-1.51] 1.12 [0.44-2.83] 1.41 [0.53-3.72]
Aberrant Motor Behavior 96 38.7 0.71 [0.44-1.16] 1.51 [0.61-3.78] 1.04 [0.39-2.78]
Sleep Disturbances 54 21.8 0.99 [0.57-1.70] 1.20 [0.43-3.31] 0.96 [0.30-3.11]
Eating Disturbances 50 20.2 1.42 [0.84-2.42] 0.57 [0.16-2.02] 0.48 [0.10-2.19]
aOdds Ratios for val66met are for the effect of Met-allele dose (2,1,0).
bOdds Ratios for for C270T and A712G are for carrier status of the less common allele (C270T-T, A712G-A).
cGenotype significantly increases risk for symptom, p<.05.
*No carriers of less common allele exhibited Elation.
(n =248)
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